Assessment of Wild-Type Cardiac Amyloidosis and AA Amyloidosis with SUDOSCAN® - JFMA 2020 Study

JFMA 2020: A Multidisciplinary Conference on Amyloidosis in the French Language.

In the recent virtual Multidisciplinary French speaking day of Amyloidosis, SUDOSCAN® was presented and showcased its utility in detecting autonomic peripheral neuropathy in AA amyloidosis and wild-type cardiac amyloidosis. Amyloidosis is a rare disease caused by amyloid protein deposits in organs. During the congress, S. Deshayes from Caen Hospital and M. Kharoubi from Henri Mondor University Hospital presented studies on using SUDOSCAN® to detect autonomic neuropathy in AA amyloidosis and wild-type cardiac amyloidosis, respectively. The studies showed promising results in using SUDOSCAN® to monitor and manage these patients. The findings from the studies on wild-type cardiac amyloidosis emphasized the significance of SUDOSCAN® in daily cardiology practice, as it could help identify patients at a higher risk of poor outcomes and optimize their management and monitoring.

Congress session presentation available below:

[1] M. Kharoubi et al (T.Damy). Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild-type cardiac amyloidosis. ESC Heart Failure (2020). Article available here.